NDAINTRAVENOUSPOWDER
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
GOZELLIX (gozetotide) by Innovation Pharmaceuticals is 68 gozetotide binds to psma. First approved in 2025.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GOZELLIX (gozetotide) is a Gallium-68 positron emission tomography (PET) imaging agent that binds to PSMA (prostate-specific membrane antigen) expressed on malignant prostate cancer cells. It enables diagnostic visualization of PSMA-positive lesions in patients with prostate cancer. The agent combines a PSMA-targeting peptide with a β+ emitting radionuclide for PET imaging.
Growth8.9 years to LOE
Recently approved with no established competitive pressure; early-stage growth phase offers opportunity to build brand infrastructure and establish market position.
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows positron emission tomography.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GOZELLIX presents an early-stage career opportunity in a specialized oncology imaging segment with no direct competition at launch. Working on this product means building foundational brand infrastructure, establishing diagnostic pathways, and developing market awareness in a niche but high-value prostate cancer imaging space.
Brand Manager
Worked on GOZELLIX at Innovation Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.